S. Boyce

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 460 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein

G. R. Dawson, Guy R. Seabrook, Hui Zheng et al. · Neuroscience · 1999 · 363 citations

Life Sciences, Neurobiology, Neuroscience +17

Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn

S. Boyce, A. C. Wyatt, J.K. Webb et al. · Neuropharmacology · 1999 · 338 citations

Life Sciences, Neuroscience, Pharmacology +17